摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

9-carbomethoxymethyl-2-(2-fluorophenyl)-7,8,9,10-tetrahydropyrido[3,4-e][1,2,4]triazolo[1,5-c]pyrimidin-5(6H)one | 116799-28-1

中文名称
——
中文别名
——
英文名称
9-carbomethoxymethyl-2-(2-fluorophenyl)-7,8,9,10-tetrahydropyrido[3,4-e][1,2,4]triazolo[1,5-c]pyrimidin-5(6H)one
英文别名
methyl 2-[4-(2-fluorophenyl)-7-oxo-3,5,6,8,12-pentazatricyclo[7.4.0.02,6]trideca-1(9),2,4-trien-12-yl]acetate
9-carbomethoxymethyl-2-(2-fluorophenyl)-7,8,9,10-tetrahydropyrido[3,4-e][1,2,4]triazolo[1,5-c]pyrimidin-5(6H)one化学式
CAS
116799-28-1
化学式
C17H16FN5O3
mdl
——
分子量
357.344
InChiKey
PKNSCGBAIJDMKG-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1
  • 重原子数:
    26
  • 可旋转键数:
    4
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.29
  • 拓扑面积:
    89.4
  • 氢给体数:
    1
  • 氢受体数:
    7

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    9-carbomethoxymethyl-2-(2-fluorophenyl)-7,8,9,10-tetrahydropyrido[3,4-e][1,2,4]triazolo[1,5-c]pyrimidin-5(6H)onesodium hydroxide氮气 、 9-carboxymethyl-2-(2-fluorophenyl) 作用下, 以 乙醇 为溶剂, 反应 2.0h, 以to produce the solid 9-carboxymethyl-2-(2-fluorophenyl)-7,8,9,10-tetrahydropyrido[3,4-e][(1,2,4]triazolo[1,5-c]pyrimidin-5(6H)one的产率得到[1,2,4]噻唑并[1,5-c]嘧啶-5(6h)-酮
    参考文献:
    名称:
    2-substituted-e-fused-[1,2,4]triazolo[1,5-c]pyrimidines, pharmaceutical
    摘要:
    本发明涉及一种公式为##STR1##的化合物,其中R.sub.1是可选择取代的苯基、吡啶基、噻吩基、呋喃基、吡咯基、噻唑基或核糖核苷基;X是氧、NR或硫;R是氢、低碳基、低烯基或低炔基;环A是(a)可选择取代的5-8成员单环烯1,2-二基;(b)公式为##STR2##的可选择取代的碳-双环环;其中n和m各自独立地为一或二;或(c)有一个或两个杂原子的可选择取代的5-6成员杂环,其原子从碳、氧、氮和硫中选择。还公开了上述化合物、互变异构体和药学上可接受的盐;其组合物;以及使用这些化合物、互变异构体或盐的方法。
    公开号:
    US04831013A1
  • 作为产物:
    参考文献:
    名称:
    Anxiolytic properties of certain annelated [1,2,4]triazolo[1,5-c]pyrimidin-5(6H)-ones
    摘要:
    Modification of the benzodiazepine (BZ) receptor binding template 2-aryl[1,2,4]triazolo[1,5-c]quinazolin-5(6H)-one by replacement of the annelated benzene ring with various alicyclic and heterocyclic moieties led to novel structures with potent BZ receptor binding affinity. High affinity was found in some cycloalkyl-annelated [1,2,4]triazolo-[1,5-c]pyrimidin-5(6H)-ones and in some 7,8,9,10-tetrahydropyrido[3,4-e][1,2,4]triazolo[1,5-c]pyrimidin-5(6H)-ones, in which the degree of activity was strongly dependent on the N-substituent in the 9-position. Nine compounds with BZ receptor IC50 binding affinity values equal or superior to diazepam were evaluated in secondary screening. One of these, 9-benzyl-2-phenyl-7,8,9,10-tetrahydropyrido[3,4-e]?? [1,2,4]triazolo[1,5-c]pyrimidin-5(6H)-one, showed good activity in rats as a potential anxiolytic agent without sedative liability. However, it increased the rotorod deficit produced by ethanol at anxiolytic doses, an indication of alcohol interaction. Thus, none of the compounds showed an advantage over CGS 9896 (Yokoyama et al. J. Med. Chem. 1982, 25, 337-339), which is free of sedative and alcohol interaction potential as measured by the test procedures described.
    DOI:
    10.1021/jm00113a032
点击查看最新优质反应信息

文献信息

  • 2-Substituted-e-fused-[1,2,4]-triazolo[1,5-c] pyrimidines, pharmaceutical compositions, and uses thereof
    申请人:CIBA-GEIGY AG
    公开号:EP0263071A1
    公开(公告)日:1988-04-06
    Compounds of the formula wherein R1 is optionally substituted phenyl, pyridyl, thienyl, furyl, pyrrolyl, thiazolyl, or ribofuranosyl; X is oxygen, NR, or sulfur: R is hydrogen, lower alkyl, lower alkenyl, or lower alkynyl; and ring A is a) an optionally substituted 5-8 membered monocycloalken-1,2-diyl; b) an optionally substituted carbob- icyclic ring of the formula. wherein n and m are each independently one or two; or c) an optionally substituted 5-6 membered heterocycle having one or two heteroatoms, the atoms of which are selected from carbon, oxygen, nitrogen, and sulfur. Also disclosed are tautomers of the above and pharmaceutically acceptable salts; compositions thereof; and methods of using the compounds, tautomer, or salts.
    式中的化合物 其中 R1 是任选取代的苯基、吡啶基、噻吩基、呋喃基、吡咯基、噻唑基或呋喃核糖基;X 是氧、NR 或硫:R 是氢、低级烷基、低级烯基或低级炔基;以及环 A 是 a)任选取代的 5-8 位单环烯-1,2-二基;b)式中任选取代的碳冰环。 其中 n 和 m 各自独立地为一个或两个;或 c) 具有一个或两个杂原子的任选取代的 5-6 分子杂环,这些杂原子选自碳、氧、氮和硫。还公开了上述化合物的同系物和药学上可接受的盐;其组合物;以及使用这些化合物、同系物或盐的方法。
  • FRANCIS, JOHN E.
    作者:FRANCIS, JOHN E.
    DOI:——
    日期:——
  • US4831013A
    申请人:——
    公开号:US4831013A
    公开(公告)日:1989-05-16
  • [EN] 2-SUBSTITUTED-E-FUSED-(1,2,4)TRIAZOLO(1,5-C)PYRIMIDINES PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
    申请人:CIBA-GEIGY AG
    公开号:WO1988002370A1
    公开(公告)日:1988-04-07
    (EN) Compounds of formula (I), wherein R1 is optionally substituted phenyl, pyridyl, thienyl, furyl, pyrrolyl, thiazolyl, or ribofuranosyl; X is oxygen, NR, or sulfur; R is hydrogen, lower alkyl, lower alkenyl, or lower alkynyl; and ring A is a) an optionally substituted 5-8 membered monocycloalken-1,2-diyl; b) an optionally substituted carbobicyclic ring of formula (II), wherein n and m are each independently one or two; or c) an optionally substituted 5-6 membered heterocycle having one or two heteroatoms, the atoms of which are selected from carbon, oxygen, nitrogen, and sulfur. Also disclosed are tautomers of the above and pharmaceutically acceptable salts; compositions thereof; and methods of using the compounds, tautomer, or salts.(FR) Composés présentant la formule (I) dans laquelle R1 est, au choix, un phényle substitué, un pyridyle, un thiényle, un furyle, un pyrrolyle, un thiazolyle ou un ribofuranosyle; X est l'oxygène, NR ou le soufre; R est l'hydrogène, un alkyle inférieur, un alcynyle inférieur ou alkyle inférieur; et le cycle A est a) un monocycloalcène-1,2-diyle à 5 à 8 côtés, éventuellement substitué; b) un cycle carbobicyclique, éventuellement substitué, de formule (II) dans laquelle n et m représentent indépendamment 1 ou 2; ou c) un hétérocycle de 5 à 6 côtés éventuellement substitué comprenant un ou deux hétéro-atomes, et dont les atomes sont choisis parmi le carbone, l'oxygène, l'azote et le soufre. Sont également décrits des tautomères de ces composés ainsi que des sels pharmaceutiques; compositions comprenant ces composés et procédés utilisant les composés, leurs tautomères ou leurs sels.
  • Anxiolytic properties of certain annelated [1,2,4]triazolo[1,5-c]pyrimidin-5(6H)-ones
    作者:John E. Francis、Debra A. Bennett、James L. Hyun、Stephen L. Rovinski、Caryl L. Amrick、Patricia S. Loo、Deborah Murphy、Robert F. Neale、Douglas E. Wilson
    DOI:10.1021/jm00113a032
    日期:1991.9
    Modification of the benzodiazepine (BZ) receptor binding template 2-aryl[1,2,4]triazolo[1,5-c]quinazolin-5(6H)-one by replacement of the annelated benzene ring with various alicyclic and heterocyclic moieties led to novel structures with potent BZ receptor binding affinity. High affinity was found in some cycloalkyl-annelated [1,2,4]triazolo-[1,5-c]pyrimidin-5(6H)-ones and in some 7,8,9,10-tetrahydropyrido[3,4-e][1,2,4]triazolo[1,5-c]pyrimidin-5(6H)-ones, in which the degree of activity was strongly dependent on the N-substituent in the 9-position. Nine compounds with BZ receptor IC50 binding affinity values equal or superior to diazepam were evaluated in secondary screening. One of these, 9-benzyl-2-phenyl-7,8,9,10-tetrahydropyrido[3,4-e]?? [1,2,4]triazolo[1,5-c]pyrimidin-5(6H)-one, showed good activity in rats as a potential anxiolytic agent without sedative liability. However, it increased the rotorod deficit produced by ethanol at anxiolytic doses, an indication of alcohol interaction. Thus, none of the compounds showed an advantage over CGS 9896 (Yokoyama et al. J. Med. Chem. 1982, 25, 337-339), which is free of sedative and alcohol interaction potential as measured by the test procedures described.
查看更多

同类化合物

(甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (R)-乙基N-甲酰基-N-(1-苯乙基)甘氨酸 (R)-丙酰肉碱-d3氯化物 (R)-4-N-Cbz-哌嗪-2-甲酸甲酯 (R)-3-氨基-2-苄基丙酸盐酸盐 (R)-1-(3-溴-2-甲基-1-氧丙基)-L-脯氨酸 (N-[(苄氧基)羰基]丙氨酰-N〜5〜-(diaminomethylidene)鸟氨酸) (6-氯-2-吲哚基甲基)乙酰氨基丙二酸二乙酯 (4R)-N-亚硝基噻唑烷-4-羧酸 (3R)-1-噻-4-氮杂螺[4.4]壬烷-3-羧酸 (3-硝基-1H-1,2,4-三唑-1-基)乙酸乙酯 (2S,3S,5S)-2-氨基-3-羟基-1,6-二苯己烷-5-N-氨基甲酰基-L-缬氨酸 (2S,3S)-3-((S)-1-((1-(4-氟苯基)-1H-1,2,3-三唑-4-基)-甲基氨基)-1-氧-3-(噻唑-4-基)丙-2-基氨基甲酰基)-环氧乙烷-2-羧酸 (2S)-2,6-二氨基-N-[4-(5-氟-1,3-苯并噻唑-2-基)-2-甲基苯基]己酰胺二盐酸盐 (2S)-2-氨基-3-甲基-N-2-吡啶基丁酰胺 (2S)-2-氨基-3,3-二甲基-N-(苯基甲基)丁酰胺, (2S,4R)-1-((S)-2-氨基-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺盐酸盐 (2R,3'S)苯那普利叔丁基酯d5 (2R)-2-氨基-3,3-二甲基-N-(苯甲基)丁酰胺 (2-氯丙烯基)草酰氯 (1S,3S,5S)-2-Boc-2-氮杂双环[3.1.0]己烷-3-羧酸 (1R,4R,5S,6R)-4-氨基-2-氧杂双环[3.1.0]己烷-4,6-二羧酸 齐特巴坦 齐德巴坦钠盐 齐墩果-12-烯-28-酸,2,3-二羟基-,苯基甲基酯,(2a,3a)- 齐墩果-12-烯-28-酸,2,3-二羟基-,羧基甲基酯,(2a,3b)-(9CI) 黄酮-8-乙酸二甲氨基乙基酯 黄荧菌素 黄体生成激素释放激素 (1-5) 酰肼 黄体瑞林 麦醇溶蛋白 麦角硫因 麦芽聚糖六乙酸酯 麦根酸 麦撒奎 鹅膏氨酸 鹅膏氨酸 鸦胆子酸A甲酯 鸦胆子酸A 鸟氨酸缩合物